Sarbecoviruses disease research hub

Phase 1 (sequential)/2a (parallel), double-blind, multicenter, randomized, controlled study to evaluate the safety and immunogenicity of two administrations of OVX033 sarbecovirus candidate vaccine, given intramuscularly (IM) at one-month interval, at three dose levels, in comparison to placebo, in subjects aged 18 years and older

This study is testing a new vaccine called OVX033 for sarbecoviruses, which include viruses like the one that causes COVID-19. Participants aged 18 and over will receive the vaccine or a dummy injection, to see how safe it is and how well it helps their immune system fight off these viruses.